Scinovex
article Open AccessTop 1% cited

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis

Hepatology · 1999 · Vol. 30(6) · pp. 1356–1362
Paul AnguloJill C. KeachKenneth P. BattsKeith D. Lindor

Abstract

Nonalcoholic steatohepatitis (NASH) may present with increased hepatic fibrosis progressing to end-stage liver disease. No factors that determine increasing fibrosis and histologically advanced disease have been recognized, thus, liver biopsy is recommended in all patients for diagnosis and prognosis. Our aim was to identify independent predictors of severe hepatic fibrosis in patients with NASH. One hundred and forty-four patients were studied. All patients underwent liver biopsy. Clinical and biochemical variables were examined with univariate and multivariate analysis. Thirty-seven (26%) patients had no abnormal fibrosis, 53 (37%) had mild fibrosis, 15 (10%) had moderate fibrosis, 14 (10%) had bridging fibrosis, and 25 (17%) had cirrhosis. In multivariate analysis, older age (P =. 001), obesity (P =.002), diabetes mellitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ratio greater than 1 (P =.03) were significant predictors of severe liver fibrosis (bridging/cirrhosis). Body mass index (P =.003) was the only independent predictor of the degree of fat infiltration. Increased transferrin saturation correlated positively with the severity of fibrosis (P =.02) in univariate analysis, and there was a trend for more female patients among those with more advanced fibrosis (P =. 09). However, iron studies or gender were not significant when controlled for age, obesity, diabetes, and AST/ALT ratio. In conclusion, older age, obesity, and presence of diabetes mellitus help identify those NASH patients who might have severe liver fibrosis. This is the subgroup of patients with NASH who would be expected to derive the most benefit from having a liver biopsy and considering investigational therapies.

Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health EffectsLiver Diseases and ImmunityMedicineInternal medicineGastroenterologyFibrosisCirrhosisLiver biopsyDiabetes mellitusUnivariate analysisNonalcoholic fatty liver diseaseSteatohepatitis

MeSH terms

AdolescentAdultAge FactorsAgedAlcoholismAnalysis of VarianceBiopsyChildDecision TreesDiabetes MellitusFatty LiverFemaleHumansLiverLiver Cirrhosis
Citations
1,607
FWCI
21.46
field-weighted impact
References
51
Percentile
100%
vs. same field & year
Citations per year
Cited by
Evaluation of Liver Fibrosis: A Concise Review
The American Journal of Gastroenterology · 2004 · 622 citations
Molecular pathways of nonalcoholic fatty liver disease development and progression
Cellular and Molecular Life Sciences · 2018 · 588 citations
Metformin in the treatment of patients with non‐alcoholic steatohepatitis
Alimentary Pharmacology & Therapeutics · 2004 · 406 citations
Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis
World Journal of Gastroenterology · 2008 · 695 citations
Metformin in the treatment of non‐alcoholic steatohepatitis: a pilot open label trial
Alimentary Pharmacology & Therapeutics · 2004 · 371 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.